Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Recruiting now · Not applicable

Conditions studied: Myelodysplastic Syndromes

In brief

This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.

Key facts

Study ID

NCT04587856

Run by

Gruppo Italiano Malattie EMatologiche dell'Adulto

People needed

38

Starts

2021-02-12

Expected to finish

2025-03-01

Last updated by the study team

2024-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of MDS according to 2016 WHO criteria
• Aged 18y or older
• Patients who will receive allogeneic stem cell transplantation (HSCT)
• Signed written informed consent according to ICH/EU/GCP and national local laws

You may not qualify if…

• Second HSCT procedure.

Where it is running

• Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto — Bari, Italy (enrolling)
• Unità di Ricerca e di Malattie del sangue - Ematologia S. Luca Vecchio — Florence, Italy (enrolling)
• AOU San Martino-IST-Ematologia 1 — Genova, Italy (enrolling)
• Sezione di Ematologia - Ospedale S.Maria della Misericordia — Perugia, Italy (enrolling)
• Dip. di Medicina Trasl. E di Precisione - U.O.C. Ematologia — Roma, Italy (enrolling)
• Policlinico Tor Vergata — Roma, Italy (enrolling)
• Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia — Rozzano, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.